Growth Hormone to Improve the Clinical Outcome of Assisted Fertility in Young Patients With Decreased Ovarian Reserve

Nanjing University

Status

Enrolling

Conditions

Infertility

Treatments

Drug: Growth hormone

Study type

Interventional

Funder types

Other

Identifiers

NCT05585177

SZ-2022-GH

Details and patient eligibility

About

This study was a prospective randomized controlled trial. Patients aged <35 years with decreased clinical reserve function (AFC<5, Follicle stimulating hormone > 10miu/ml, Anti-mullerian hormone < 1.1μg/L) and receiving IVF/ICSI assisted ovulation induction in our hospital were included in this study. After randomization using Excel(Microsoft Corporation, Albuquerque, USA), these patients were divided into two groups. Group A was the experimental group, which was treated with growth hormone for 3 months (2 units per day) before IVF/ICSI. Group B was the control group, which was directly assisted by IVF/ICSI.

Enrollment

120 estimated patients

Sex

Female

Ages

20 to 34 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age < 35 years;
AFC≤5
Follicle stimulating hormone > 10miu/ml;
Anti-mullerian hormone < 1.1μg/L

(2 out of 2-4 items can be met)

Exclusion criteria

Severe male factors: spermatozoa collected by testicular sperm aspiration (TESA) or percutaneous epididymal sperm aspiration (PESA) was used for intracytoplasmic sperm injection (ICSI) cycle of single spermatozoa;
Patients with severe adenomyosis, endometriosis, intrauterine adhesions and other diseases that significantly affect embryo implantation;
Diabetes mellitus, insulin resistance;
chromosomal karyotype abnormality in either spouse;
Any pregnancy or contraindications of assisted reproductive technology;